Liminatus Pharma, Inc. Warrants
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 201… Read more
Liminatus Pharma, Inc. Warrants (LIMNW) - Total Liabilities
Latest total liabilities as of September 2025: $2.99 Million USD
Based on the latest financial reports, Liminatus Pharma, Inc. Warrants (LIMNW) has total liabilities worth $2.99 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Liminatus Pharma, Inc. Warrants - Total Liabilities Trend (2021–2024)
This chart illustrates how Liminatus Pharma, Inc. Warrants's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Liminatus Pharma, Inc. Warrants Competitors by Total Liabilities
The table below lists competitors of Liminatus Pharma, Inc. Warrants ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eco Depot Inc
PINK:ECDP
|
USA | $12.50 Million |
|
Sassy Gold Corp.
OTCQB:SSYRD
|
USA | $427.07K |
|
CENTRAL PETROLEUM (C9J.SG)
STU:C9J
|
Germany | €71.08 Million |
|
Caledonian Holdings PLC
LSE:CHP
|
UK | GBX6.00K |
|
TANFIELD GRP
BE:XS3A
|
Germany | €72.00K |
Liability Composition Analysis (2021–2024)
This chart breaks down Liminatus Pharma, Inc. Warrants's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Liminatus Pharma, Inc. Warrants's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Liminatus Pharma, Inc. Warrants (2021–2024)
The table below shows the annual total liabilities of Liminatus Pharma, Inc. Warrants from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $18.70 Million | +3.68% |
| 2023-12-31 | $18.04 Million | +2.17% |
| 2022-12-31 | $17.65 Million | -18.16% |
| 2021-12-31 | $21.57 Million | -- |